vs

Side-by-side financial comparison of Abbott Laboratories (ABT) and National Vision Holdings, Inc. (EYE). Click either name above to swap in a different company.

Abbott Laboratories is the larger business by last-quarter revenue ($11.5B vs $487.3M, roughly 23.5× National Vision Holdings, Inc.). Abbott Laboratories runs the higher net margin — 15.5% vs 0.7%, a 14.8% gap on every dollar of revenue. On growth, National Vision Holdings, Inc. posted the faster year-over-year revenue change (7.9% vs 4.4%). Abbott Laboratories produced more free cash flow last quarter ($2.6B vs $30.3M). Over the past eight quarters, National Vision Holdings, Inc.'s revenue compounded faster (7.6% CAGR vs 7.2%).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Vision Research is an international company that manufactures high-speed digital cameras based in Wayne, New Jersey. Their cameras are marketed under the Phantom brand, and are used in a broad variety of industries including: defense, industrial product development, manufacturing, automotive, scientific research, and entertainment. Vision Research is a business unit of the Materials Analysis Division of Ametek Inc., a global manufacturer of electronic instruments and electromechanical devices.

ABT vs EYE — Head-to-Head

Bigger by revenue
ABT
ABT
23.5× larger
ABT
$11.5B
$487.3M
EYE
Growing faster (revenue YoY)
EYE
EYE
+3.5% gap
EYE
7.9%
4.4%
ABT
Higher net margin
ABT
ABT
14.8% more per $
ABT
15.5%
0.7%
EYE
More free cash flow
ABT
ABT
$2.6B more FCF
ABT
$2.6B
$30.3M
EYE
Faster 2-yr revenue CAGR
EYE
EYE
Annualised
EYE
7.6%
7.2%
ABT

Income Statement — Q4 2025 vs Q3 2026

Metric
ABT
ABT
EYE
EYE
Revenue
$11.5B
$487.3M
Net Profit
$1.8B
$3.4M
Gross Margin
57.0%
Operating Margin
19.6%
2.0%
Net Margin
15.5%
0.7%
Revenue YoY
4.4%
7.9%
Net Profit YoY
-80.8%
139.8%
EPS (diluted)
$1.01
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABT
ABT
EYE
EYE
Q4 25
$11.5B
Q3 25
$11.4B
$487.3M
Q2 25
$11.1B
$486.4M
Q1 25
$10.4B
$510.3M
Q4 24
$11.0B
$437.3M
Q3 24
$10.6B
$451.5M
Q2 24
$10.4B
$451.7M
Q1 24
$10.0B
$482.8M
Net Profit
ABT
ABT
EYE
EYE
Q4 25
$1.8B
Q3 25
$1.6B
$3.4M
Q2 25
$1.8B
$8.7M
Q1 25
$1.3B
$14.2M
Q4 24
$9.2B
$-28.6M
Q3 24
$1.6B
$-8.5M
Q2 24
$1.3B
$-3.1M
Q1 24
$1.2B
$11.7M
Gross Margin
ABT
ABT
EYE
EYE
Q4 25
57.0%
Q3 25
55.4%
Q2 25
56.4%
Q1 25
56.9%
Q4 24
55.0%
Q3 24
55.8%
Q2 24
55.6%
Q1 24
55.2%
Operating Margin
ABT
ABT
EYE
EYE
Q4 25
19.6%
Q3 25
18.1%
2.0%
Q2 25
18.4%
3.4%
Q1 25
16.3%
5.1%
Q4 24
17.4%
-5.8%
Q3 24
17.5%
-2.0%
Q2 24
16.1%
0.1%
Q1 24
13.9%
4.9%
Net Margin
ABT
ABT
EYE
EYE
Q4 25
15.5%
Q3 25
14.5%
0.7%
Q2 25
16.0%
1.8%
Q1 25
12.8%
2.8%
Q4 24
84.1%
-6.5%
Q3 24
15.5%
-1.9%
Q2 24
12.5%
-0.7%
Q1 24
12.3%
2.4%
EPS (diluted)
ABT
ABT
EYE
EYE
Q4 25
$1.01
Q3 25
$0.94
$0.04
Q2 25
$1.01
$0.11
Q1 25
$0.76
$0.18
Q4 24
$5.26
$-0.36
Q3 24
$0.94
$-0.11
Q2 24
$0.74
$-0.04
Q1 24
$0.70
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABT
ABT
EYE
EYE
Cash + ST InvestmentsLiquidity on hand
$8.9B
$56.0M
Total DebtLower is stronger
$12.9B
$236.5M
Stockholders' EquityBook value
$52.1B
$858.8M
Total Assets
$86.7B
$2.0B
Debt / EquityLower = less leverage
0.25×
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABT
ABT
EYE
EYE
Q4 25
$8.9B
Q3 25
$7.7B
$56.0M
Q2 25
$7.3B
$48.5M
Q1 25
$6.8B
$80.0M
Q4 24
$8.0B
$73.9M
Q3 24
$7.8B
$81.2M
Q2 24
$7.2B
$179.5M
Q1 24
$6.7B
$150.1M
Total Debt
ABT
ABT
EYE
EYE
Q4 25
$12.9B
Q3 25
$236.5M
Q2 25
$255.6M
Q1 25
$244.7M
Q4 24
$14.1B
$248.6M
Q3 24
$252.8M
Q2 24
$143.9M
Q1 24
$448.6M
Stockholders' Equity
ABT
ABT
EYE
EYE
Q4 25
$52.1B
Q3 25
$51.0B
$858.8M
Q2 25
$50.6B
$850.6M
Q1 25
$48.8B
$836.2M
Q4 24
$47.7B
$816.3M
Q3 24
$39.8B
$840.0M
Q2 24
$39.3B
$843.4M
Q1 24
$38.8B
$841.3M
Total Assets
ABT
ABT
EYE
EYE
Q4 25
$86.7B
Q3 25
$84.2B
$2.0B
Q2 25
$84.0B
$2.0B
Q1 25
$81.4B
$2.0B
Q4 24
$81.4B
$2.0B
Q3 24
$74.4B
$2.0B
Q2 24
$73.0B
$2.1B
Q1 24
$72.5B
$2.2B
Debt / Equity
ABT
ABT
EYE
EYE
Q4 25
0.25×
Q3 25
0.28×
Q2 25
0.30×
Q1 25
0.29×
Q4 24
0.30×
0.30×
Q3 24
0.30×
Q2 24
0.17×
Q1 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABT
ABT
EYE
EYE
Operating Cash FlowLast quarter
$3.3B
$46.6M
Free Cash FlowOCF − Capex
$2.6B
$30.3M
FCF MarginFCF / Revenue
22.9%
6.2%
Capex IntensityCapex / Revenue
6.0%
3.4%
Cash ConversionOCF / Net Profit
1.87×
13.83×
TTM Free Cash FlowTrailing 4 quarters
$7.4B
$83.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABT
ABT
EYE
EYE
Q4 25
$3.3B
Q3 25
$2.8B
$46.6M
Q2 25
$2.0B
$54.3M
Q1 25
$1.4B
$32.2M
Q4 24
$2.9B
$30.3M
Q3 24
$2.7B
$27.9M
Q2 24
$2.0B
$51.5M
Q1 24
$1.0B
$24.0M
Free Cash Flow
ABT
ABT
EYE
EYE
Q4 25
$2.6B
Q3 25
$2.3B
$30.3M
Q2 25
$1.5B
$42.4M
Q1 25
$933.0M
$12.0M
Q4 24
$2.1B
$-1.7M
Q3 24
$2.1B
$4.1M
Q2 24
$1.4B
$31.9M
Q1 24
$627.0M
$4.0M
FCF Margin
ABT
ABT
EYE
EYE
Q4 25
22.9%
Q3 25
20.2%
6.2%
Q2 25
13.9%
8.7%
Q1 25
9.0%
2.4%
Q4 24
19.6%
-0.4%
Q3 24
20.2%
0.9%
Q2 24
13.8%
7.1%
Q1 24
6.3%
0.8%
Capex Intensity
ABT
ABT
EYE
EYE
Q4 25
6.0%
Q3 25
4.4%
3.4%
Q2 25
4.5%
2.4%
Q1 25
4.7%
4.0%
Q4 24
6.6%
7.3%
Q3 24
5.2%
5.3%
Q2 24
5.1%
4.3%
Q1 24
4.0%
4.1%
Cash Conversion
ABT
ABT
EYE
EYE
Q4 25
1.87×
Q3 25
1.70×
13.83×
Q2 25
1.15×
6.22×
Q1 25
1.07×
2.27×
Q4 24
0.31×
Q3 24
1.64×
Q2 24
1.51×
Q1 24
0.84×
2.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons